ReviewTherapeutic advances in urology2016
Testosterone deficiency in the aging male.
Review in Therapeutic advances in urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- "Low Testosterone Levels in Body Fluids Are Associated With Chronic Periodontitis".American journal of men's health · 2017Pooled it
- A Combination ofInternational journal of medical sciences · 2025Trial
- A proprietary blend of standardizedInternational journal of medical sciences · 2022Trial
- Sleep restriction and testosterone concentrations in young healthy males: randomized controlled studies of acute and chronic short sleep.Sleep health · 2019Trial
- The influence of sex steroids on cognition in elderly men.Clinics (Sao Paulo, Brazil) · 2026Article
- Amino acid profiles, aging, and sex hormone interactions in the elderly Iranian population: a metabolomics study.Journal of diabetes and metabolic disorders · 2025Article
- The effects of testicular aging on Leydig cells and the application of stem cells in restoring Leydig cells function.Reproductive biology and endocrinology : RB&E · 2025Review
- Age-related decline in behavior and reproductive health in male mice.Scientific reports · 2025Article
- Sex differences in cognitive performance persist into your 80s.GeroScience · 2025Article
- Differential temporal decline of cerebral oxytocin and μ-opioid receptor density during the aging process in mice.The European journal of neuroscience · 2024Article
- Age-related testosterone decline: mechanisms and intervention strategies.Reproductive biology and endocrinology : RB&E · 2024Review
- Article
- Low testosterone levels relate to poorer cognitive function in women in an APOE-ε4-dependant manner.Biology of sex differences · 2024Article
- Article
- A literature review onHeliyon · 2023Review
- The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice.The world journal of men's health · 2023Review
- Article
- Testosterone deficiency and the aging male.International journal of impotence research · 2022Review
- Plasma metabolome study reveals metabolic changes induced by pharmacological castration and testosterone supplementation in healthy young men.Scientific reports · 2022Article
- Androgens and COVID-19.Journal of cosmetic dermatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment for hypogonadism is on the rise, particularly in the aging population. Yet treatment in this population represents a unique challenge to clinicians. The physiology of normal aging is complex and often shares the same, often vague, symptoms of hypogonadism. In older men, a highly prevalent burden of comorbid medical conditions and polypharmacy complicates the differentiation of signs and symptoms of hypogonadism from those of normal aging, yet this differentiation is essential to the diagnosis of hypogonadism. Even in older patients with unequivocally symptomatic hypogonadism, the clinician must navigate the potential benefits and risks of treatment that are not clearly defined in older men. More recently, a greater awareness of the potential risks associated with treatment in older men, particularly in regard to cardiovascular risk and mortality, have been appreciated with recent changes in the US Food and Drug Administration recommendations for use of testosterone in aging men. The aim of this review is to provide a framework for the clinician evaluating testosterone deficiency in older men in order to identify correctly and treat clinically significant hypogonadism in this unique population while minimizing treatment-associated harm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.